CN1142940C - Pharmaceutical compsns. containing an MPL ligand - Google Patents

Pharmaceutical compsns. containing an MPL ligand Download PDF

Info

Publication number
CN1142940C
CN1142940C CNB971802777A CN97180277A CN1142940C CN 1142940 C CN1142940 C CN 1142940C CN B971802777 A CNB971802777 A CN B971802777A CN 97180277 A CN97180277 A CN 97180277A CN 1142940 C CN1142940 C CN 1142940C
Authority
CN
China
Prior art keywords
composition
amino acid
leu
sorbitol powder
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971802777A
Other languages
Chinese (zh)
Other versions
CN1239480A (en
Inventor
D・N・布雷姆斯
D·N·布雷姆斯
特雷乌黑特
M·J·特雷乌黑特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN1239480A publication Critical patent/CN1239480A/en
Application granted granted Critical
Publication of CN1142940C publication Critical patent/CN1142940C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The subject invention relates to compositions of mpl ligands, comprising a full-length or truncated mpl ligand having a sequence of amino acids corresponding to amino acids 7-151 through 1-332, inclusive, of native human mpl ligand, optionally covalently linked to at least one water-soluble polymer; a buffering agent selected from glutamate, phosphate, histidine, imidazole, and acetate; an excipient selected from sorbitol, sucrose, mannitol, glycerol, polyethylene glycol, and non-polar amino acids; optionally, a detergent or lipid such as Tween; optionally, an antioxidant or chelating agent selected from glutathione, methionine, citrate and EDTA; and having a pH preferably ranging from 5.0 to 6.0 (inclusive). Such compositions may be liquid (preferably, aqueous), frozen (preferably, aqueous), or lyophilized.

Description

The pharmaceutical composition that contains mpl ligand
Invention field
The present invention relates to contain the composition of mpl part, its composition is suitable for medicinal.
Background of invention
Natural people mpl part is the cytokine of cloning recently, is the main conditioning agent of circulation platelet levels.Referring to Bartley, T.D. etc., cell (Cell) 77:1117-1124 (1994); Lok, S. etc., nature (Nature) 369:565-568 (1994); De Sauvage, F.J. etc., natural 369:533-538 (1994); Miyazake, H. etc., Exp.Hematol.22:838 (1994); And Kuter, D.J. etc., PNAS USA, 91:11104-11108 (1994).The endogenous mpl part of people also is referred to as thrombopoietin (TPO) and megapoietin, is to contain 332 amino acid whose protein altogether.
Reorganization mpl part by Chinese hamster ovary (CHO) and Bacillus coli cells preparation demonstrates differential stimulus or increases megalokaryocyte and/or hematoblastic biological activity in mouse, rat and monkey body.Referring to for example, Hunt, P. etc., Blood 84 (10): 390A (1994).Block nearly biological activity in 181 amino acid whose people mpl part retention bodies from the C-end.Gained mpl part is corresponding to the amino acid fragment of 1-151 in the full length sequence up to 1-331.Also can remove preceding 6 amino acid and retains biological activity at the N-of people mpl ligandin matter end.Therefore, show that biological activity is retained among the amino acid 7-151 (including) of mature amino acid sequence of people mpl part.
The derivative of in vivo test proof mpl part has the generation of stimulation megalokaryocyte and/or hematoblastic favorable activity.Referring to disclosed PCT application WO95/26746.Especially, with water-soluble polymers for example the mpl part of polyoxyethylene glycol (" PEG ") part derivatize clinical meaning is arranged because they in vivo the life-span long and activity arranged.
The composition that contains mpl part and relevant derivative is disclosed with general fashion.Referring to disclosed PCT application WO95/26746, WO95/21919, WO95/18858, and WO95/21920.But control experiment described herein does not appear in the newspapers, and this experiment can be determined composition which kind of contains the mpl part has and be suitable for medicinal stability.This composition is significant to the mpl part is useful for human patients.Therefore, this composition need be used in current this area, gives the patient with the mpl part, and platelet levels is raise.
Summary of the invention
Therefore, the purpose of this invention is to provide the medicinal stable composition that contains the mpl part.
Another object of the present invention provides the composition that contains the mpl part to patient's administration.
In embodiments, the composition that the present invention relates to comprises: covalently bound have corresponding to the total length of the aminoacid sequence of the amino acid 7-151 to 1-332 (including) of natural human mpl part or the mpl part of brachymemma with at least a water-soluble polymers is optional; Be selected from glutaminate, phosphoric acid salt, Histidine, the buffer reagent of imidazoles and acetate; Be selected from Sorbitol Powder, sucrose, mannitol, glycerine, the vehicle of polyoxyethylene glycol and nonpolar amino acid; Randomly, stain remover Tween for example; Randomly, be selected from gsh, methionine(Met), the antioxidant of Citrate trianion and EDTA or sequestrant; Has pH preferable range 5.0-6.0 (including).Such composition can be liquid (preferably aqueous), refrigerated (preferably aqueous) or freeze dried.
Propose in the circumstantial letter that other aspects of the present invention provide below.
Brief description of drawings
Fig. 1 provides the cDNA sequence and the corresponding proteins matter sequence (SEQID NOS:1 and 2) of the endogenous mpl part of people.They contain a leader sequence (amino acid-21 is to-1), and this sequence is excised in the cDNA proteins encoded in vivo to produce maturation protein.
                       Detailed description of the invention
The invention provides the composition that contains mpl part and other reagent, it stablizes, has biologically active, is suitable for the people and uses.
In first embodiment, the present invention relates to the composition of mpl part. " mpl part " broadly refers to can specific binding and activate the mpl acceptor, thus all protein moleculars that stimulate megacaryocyte in the body and/or blood platelet to produce. In preferred embodiments, the mpl part have with from the identical amino acid sequence of people's part, the amino acid/11 of natural human sequence-332 (SEQ ID NO:2) for example. In a further preferred embodiment, the mpl part has one section amino acid sequence, described amino acid sequence is at least identical with following amino acid sequences: the amino acid 7-151 of SEQ ID NO:2, preferably corresponding to the 1-171 of SEQ ID NO:2 ± 20 amino acid (being that amino acid/11-151 is to 1-191), especially preferred 1-161 ± ten amino acid. Some particularly preferred mpl ligand species are as follows: the amino acid/11-151 of SEQ ID NO:2,1-152,1-153,1-154,1-163,1-174,1-191,1-232,1-244. Kind most preferably has the amino acid residue fragment 1-163 of SEQ ID NO:2.
The mpl part also can be with for example one or more polyethylene glycol (PEG) group materialization of deriving of one or more water-soluble poly compounds. The polymer of selecting should be water-soluble, so that its mpl part that connects (for example physiology environment) precipitation not under water environment. The example of water-soluble poly compound provides in disclosed PCT application WO95/26746, and it is incorporated by reference here.
The water-soluble poly compound can use chemical reaction to connect, the chemical reaction that for example uses those to describe in disclosed PCT application WO95/26746. Preferred connection chemical action is acidylate and alkylation. Mpl ligand derivatives of the present invention can connect a plurality of polymer molecules, for example can have 2-6, preferred 2-5. Polymeric groups is connected with protein at amino acid whose α or the amino place of ε usually, but can consider that also polymeric groups can be connected with any amino on the protein as long as reaction condition is suitable, reactivity is enough.
In preferred embodiments, single polymer molecule connects the mpl part.Under these circumstances, modified, for example be used for the active ester of acidylate or be used for alkylating aldehyde with the polymer application single reaction group of mpl part reaction, thus the may command extent of polymerization.
Polymkeric substance can be branch or ramose not.Pay the utmost attention to the therepic use of end product preparation, polymkeric substance should be that pharmacy is acceptable.Water-soluble polymers can be selected from group, polyoxyethylene glycol for example, a methoxy poly (ethylene glycol), dextran, poly--(N-V-Pyrol RC) polyoxyethylene glycol, the propylene glycol homopolymer, poly(propylene oxide)/ethylene oxide copolymer, the many alcohol of polyoxy ethylization (for example glycerine) and polyvinyl alcohol.Carry out derivatize for the mpl part by acylation reaction, the polymkeric substance of selection should have single reactive ester group.Carry out derivatize for the mpl part by reductive alkylation reaction, the polymkeric substance of selection should have single reactive aldehyde groups.Generally speaking, should not select the natural water-soluble polymers that has glycosyl residue, because of its usually through the easier preparation of Mammals recombinant expression system.Polymkeric substance can be any molecular weight, as long as it does not disturb or eliminate the biological activity of the mpl ligand derivatives that obtains substantially.
Here employed particularly preferred water-soluble polymers is a polyoxyethylene glycol, abbreviation PEG.Be any form that comprises other proteinic PEG that are used for deriving, one-(C1-C10) alkoxyl group-or aryloxy-polyoxyethylene glycol (referring to United States Patent (USP) 5252714) for example.
The peg base of mpl part turns usefulness (pegy1ation) into and can be undertaken by any reaction that peg base known in the art turns usefulness into.Referring to, for example: Focus on Growth Factor 3 (2): 4-10 (1992); EP 0154316; EP 0401384; That is quoted here turns into other relevant publications with the peg base.Preferably, the peg base turns into and uses by carrying out with the acidylate or the alkylation of reactive polyethylene glycol molecule.
Therefore, from optimized angle, the present invention relates to the mpl part of peg baseization, wherein the PEG base connects by acyl group or alkyl.As discussed above, such product can be (for example the containing 2-6, preferred 2-5 PEG group) of one-peg baseization or many-peg baseization.Polymeric groups is connected with protein at amino acid whose α or the amino place of ε usually, but comprises that also the PEG group can be connected with any amino on the protein with enough reactive behavioies under proper reaction conditions.
The PEG group of preferred molecular weight 5-50kd connects by the reductive alkylation action method.In the most preferred embodiment, it (is 20kd ± 2kd) that the PEG group molecular-weight average in the PEG-mpl part is about 20kd.
Particularly preferred mpl ligand derivatives is meant among the SEQ ID NO:2 product that is connected of the α bit amino of first residue and PEG group on amino acid/11-163 fragment, and wherein PEG is by being connected with the standard reductive alkylation reaction of PEG aldehyde reaction thing.Here the type mpl part is appointed as abbreviation " PEG-rHuMGDF ".
In preferred embodiments, the expression product of the mpl part exogenous DNA array that is transfection in the host cell; That is to say that in preferred embodiments, the mpl part is " a reorganization mpl part ".Reorganization mpl part can for example prepare in the Chinese hamster ovary celI at known any cell for this purpose.Preferred host is a bacterium, preferred especially Bacillus coli cells.According to quoted from here about the method described in the mpl part clone and the public publication of expressing, reorganization mpl part is easy to preparation.
Although the prior art personnel once reported the composition that relates to natural human mpl part (amino acid/11-332 of SEQ ID NO:2), a large amount of stability datas that none had before been reported here to be proposed as the composition components function.Therefore, although previous prediction the stability of mpl ligand combination thing, the composition with expectation stability was not also clearly disclosed when of the present invention, especially for the mpl part of the derivatize of brachymemma.
Based on the data that hereinafter provide, the inventor finds that some stable compositions comprise: what be connected with at least a water-soluble polymers covalency selectivity has corresponding to the total length of natural human mpl part amino acid fragment 7-151 to 1-332 (including) or the mpl part of brachymemma; Be selected from glutaminate, phosphoric acid salt, Histidine, the buffer reagent of imidazoles and acetate; Be selected from Sorbitol Powder, sucrose, mannitol, glycerine, the vehicle of polyoxyethylene glycol and nonpolar amino acid; Optional
Stain remover is Tween for example; Randomly, be selected from gsh, methionine(Met), the antioxidant of Citrate trianion and EDTA or sequestrant; Has pH preferable range 5.0-6.0 (including).Such composition form can be liquid (preferably aqueous), refrigerated (preferably aqueous) or freeze dried.
The concentration of this protein (mpl part) in final composition generally should be about 0.1mg/ml to 5mg/ml scope, preferred 0.2mg/ml to 3mg/ml, preferred especially 0.3-1mg/ml.
Preferably, damping fluid is the acetate of 5-20mM concentration, particularly preferably about 10 ± 2mM.The summary of concrete damping fluid and concentration is provided in the following table 1:
Table 1
Damping fluid Preferred concentration range (mM) Operation concentration range (mM) Experimental concentration (mM)
Acetate 5-20 8-12 10
Phosphoric acid salt 5-20 8-12 10
Histidine 5-20 8-12 10
The pH of composition is along with specific damping fluid changes with other factors.For the preferred pH scope that improves stability with suitable acidic buffer (for example acetate) is 4.0-6.0.Most preferred scope is 4.5-5.5, and about 5.0 is the most preferred embodiment.
Composition should also contain vehicle.Listed some vehicle of giving an example and representative concentration in the table 2:
Table 2
Vehicle Preferred concentration range (W/V) Operation concentration range (W/V) Experimental concentration (W/V)
Sorbitol Powder 3-10％ 4-6％ 5％
Sucrose 5-10％ 8-10％ 9％
Mannitol 3-10％ 4-6％ 5％
Generally, make to produce isotonic solution with a certain amount of adding vehicle.
Composition can further contain in some cases some amino acid with enhanced stability.Amino acid can be polarity or nonpolar, and nonpolar amino acid is preferred.Polare Aminosaeren for example is arginine and Methionin, and the nonpolar amino acid of giving an example is a glycine, proline(Pro) and L-Ala.
Can also contain antioxidant or sequestrant in the present composition.Preferred anti-oxidants is: EDTA, xitix, gsh, methionine(Met) and Citrate trianion.Also comprise these combination of agents, for example Citrate trianion adds EDTA.Amount with the oxygenizement that is fit to reduce or eliminate the mpl part contains such reagent.Concentration for example is: 0.1-10mM, preferred 0.5-5mM, general 1-3mM.
Can also contain stain remover or lipid in the present composition.Some representative stain removers are: the Tween trade mark of polysorbate (for example Tween20 and Tween80); Brij 35; Pluronics (for example F-127 and F-68); Sodium lauryl sulphate; Triton (for example X-100); GLYCEROL,DIMYRISTOYL PHOSPHATIDYL (DMPG); PEG Viscotrol C (for example PEG-40); Oleyl (oleth)-3-phosphoric acid salt; Diethanolamine oleyl (oleth)-10-phosphoric acid salt; Contain for example short chain of C8 (suffering) and C14 (14) lipid, the mixture of long-chain individual layer lipid vesicle (SLUV) (for example 1: 1).The amount of these stain remover/lipids generally should be enough to prevent because the mpl ligand loss that surperficial adhesion or gathering cause.Some detergent concentration of giving an example are 0.004mg/ml-50mg/mI; Preferred 0.004mg/ml-10mg/ml; 0.006mg/ml-0.060mg/ml most preferably.When the concentration of mpl part is lower, during for example especially smaller or equal to 0.2mg/ml mpl part, the needs that contain these stain remover/lipids can be bigger.
Such composition can be liquid (preferably aqueous), refrigerated (preferably aqueous) or freeze dried.
About freeze dried composition, compare with liquid composition, the possibility of the protein condenses of increase is arranged.Particularly preferred freeze dried composition contains the glutaminate of pH in the 4.0-6.0 scope, the mixture of sucrose and mannitol.Particularly preferred composition explanation is provided in the following table 3:
Table 3
Material Scope Embodiment
Glutaminate 5-20mM 10mM
Sucrose 2-10％(w/v) 6％(w/v)
Mannitol 1-5％(w/v) 2％(w/v)
pH 4.0-6.0 5.0
The present composition is " stable ", this means according to simple SEC stratographic analysis, after storing for 12 weeks under 37 ℃ of temperature, keep about at least 87%, preferably approximately 90%, most preferably about 93% complete mpl ligand derivatives (referring to table 4).This degree of stability has important practice significance, because less stability can produce the unacceptable security to the patient.
Here employed " treatment significant quantity " can produce suitable biological activity in patient's body, promptly the patient to given symptom and prescription produces curative effect.
The present composition can be systematically at parenteral, intravenously or subcutaneous administration.At this moment, the therapeutic composition that uses among the present invention can be no thermal source, physiology acceptable aqueous solution.Select concrete approach to depend on the symptom that to treat.The dosage that requires is the amount that is enough to improve patient's thrombocyte and/or megalokaryocyte level, and according to the severity of the symptom that will treat, the medication of use etc. and difference.
Those symptoms that the symptom that will treat by the inventive method and composition generally relates to there is megalokaryocyte/aleukia or expects megalokaryocyte/aleukia (for example because arranged operation).Such symptom normally lacks the result of (temporary transient or permanent) active mpl part in the body.The generic term of aleukia is a thrombopenia, so the inventive method and composition generally are used for the treatment of thrombopenia.
Thrombopenia (aleukia) is because former separately thereby existence comprises with various medicine chemotherapy and other treatment radiotherapy, operation, the illness that randomness is lost blood and other is concrete.The concrete illness of giving an example that relates to thrombopenia and can treat according to the present invention is: aplastic anemia, spontaneous thrombopenia, cause thrombocytopenic metastatic tumor, systemic lupus erythematous, splenomegaly, the Fan Keni syndromes, vitamin B12 deficiency, folic acid deficiency, May-Hegglin is unusual, Wiskott-Aldrich syndromes and paroxysmal are sent out hemoglobinuria night.And cause thrombopenia (for example AZT) for some treatment of AIDS.Some wound healing imbalances also can have increased access to benefit from platelet count.
About the aleukia of expection, for example, because following operation, mpl ligand analogs of the present invention can be in a few days ago extremely administration in several hours of needs thrombocyte.For acute situations, for example randomness and massive blood loss, the mpl ligand analogs can with the thrombocyte of blood or purifying give together with.
Mpl ligand combination thing also can provide the normal people of thrombocyte or other relevant cell to take to plan.Give the amount that can increase thrombocyte that the patient once confesses and/or relevant cell with the present composition.
Be used for the treatment of the dose plan that relates in the method for above-mentioned illness and will depend on, consider to adjust pharmaceutically-active various factors, for example age according to the attending doctor, symptom, body weight, sex and patient's diet, the severity that infects, administration time and other clinical factors are determined.Generally speaking, the per daily dose for every kg body weight should be a 0.01-1000 microgram mpl ligand analogs scope.
Be characterised in that in the morbid state of other syndromess and aleukia in treatment, the present composition can also use separately or and other cytokines, soluble M pl acceptor (being the mpl acceptor), Hemopoietic factor, interleukin-, somatomedin or antibodies are used.Expect that such composition proof is useful in IL-3 or the thrombocytopenic certain situation of GM-CSF bonded for example at the general stimulant of treatment and hemopoietic.Other megakaryocyte stimulating factors, i.e. meg-CSF, stem cell factor (SCF), leukaemia inhibitory factor (LIF), oncostatin M (OSM), perhaps other molecules with megalokaryocyte stimulating activity also can use with the mpl part.The cytokine that is used for such co-administered or the hematopoietic factor of giving an example in addition comprise IL-1 α, IL-1 β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-11, colony-stimulating factor-1 (CSF-1), GM-CSF, granulocyte colony-stimulating factor (G-CSF), EPO, interferon-' alpha ' (IFN-α), IFN-β or IFN-γ.Simultaneously or take the solubility Mammals Mpl acceptor of significant quantity continuously more usefully, in case show that having megalokaryocyte reaches mature form and just cause that megalokaryocyte is cracked into fragment and becomes hematoblastic effect.Therefore, take that to take that soluble M pl acceptor (with the deactivation analogue and make ripe megalokaryocyte produce thrombocyte) is expected behind the PEG-mpl part (to increase ripe megalokaryocyte number) again be the special effective means that stimulating platelet produces.Regulate above-mentioned dosage and can compensate supplementary component such in the therapeutic composition.Can monitor patient's the course of treatment by ordinary method.
The following examples are described the present invention more comprehensively, but do not think its scope that limits.
Embodiment 1
The data that some embodiment provided below following table 4 and 5 had been summed up.In each of these embodiment, the mpl part of test is PEG-rHuMGDF, and it contains the amino acid/11-163 of SEQ ID NO:2, with the polyethylene group of the about 20kDa of molecular-weight average in the α of the-terminal amino acid list-peg of amino place baseization.
Table 4
Prescription Pass through SEC after 37 ℃ of 12 week 1The main peak percentage ratio of measuring
Histidine, pH8.0,5% Sorbitol Powder 70
Tris, pH8.0,5% Sorbitol Powder 47
Phosphoric acid salt, pH7.0,5% Sorbitol Powder 71
Histidine, pH7.0,5% Sorbitol Powder 84
Phosphoric acid salt, pH6.0,5% Sorbitol Powder 89
Glutaminate/Histidine, pH6.0,5% Sorbitol Powder 92
Histidine, pH6.0,5% Sorbitol Powder 92
Imidazoles, pH6.0,5% Sorbitol Powder 92
Glutaminate, pH5.5,5% Sorbitol Powder 91
Glutaminate/Histidine, pH5.5,5% Sorbitol Powder 93
Acetate, pH5.0,5% Sorbitol Powder 92
Glutaminate/Histidine, pH5.0,5% Sorbitol Powder 93
Glutaminate, pH5.0,5% Sorbitol Powder 91
Histidine, pH5.0,5% Sorbitol Powder 89
Succinate, pH5.0,5% Sorbitol Powder 76
Glutaminate, pH4.0,5% Sorbitol Powder 87
Succinate, pH4.0,5% Sorbitol Powder 81
Acetate, pH4.0,5% Sorbitol Powder 77
Tartrate, pH4.0,5% Sorbitol Powder 18
Succinate, pH3.5,5% Sorbitol Powder 74
1Additional stability index is measured, and specifically, is anti-phase and the cationic exchange look
Spectrum provides analog result to SEC.
Preferred pH scope 4.0-6.0 is indicated in the minimizing of main peak percentage ratio, preferred 5.0-6.0.In addition, the buffering effect in the pH scope 4.0-6.0 shows that some damping fluids are not preferred in this scope.
Table 5
Prescription SEC after 37 ℃ of 12 week 1The main peak percentage ratio of measuring
Acetate, pH5.0,5% grade is oozed many alcohol (Sorbitol Powder) 92
Acetate, pH5.0, isotonic saline solution, monovalence and divalence (NaCl) 10
Acetate, pH5.0 waits and oozes polare Aminosaeren (Methionin) 10
Acetate, pH5.0 waits and oozes nonpolar amino acid (glycine) 84
The how alcohol of all tests comprises: Sorbitol Powder, and sucrose, glycerine, mannitol and polyoxyethylene glycol all provide analog result.
All salt (monovalence and divalence) comprising: sodium-chlor, and calcium chloride, cupric chloride, magnesium chloride, Manganous chloride tetrahydrate, nickelous chloride, zinc chloride and ferrous chloride all provide analog result.
The polare Aminosaeren of all tests comprises: arginine and Methionin all provide analog result.
The nonpolar amino acid of all tests comprises: glycine, proline(Pro) and L-Ala all provide analog result.
The antioxidant of all tests comprises: EDTA, and xitix, gsh, methionine(Met), methionine(Met)+EDTA and Citrate trianion do not show the raising greatly (referring to the embodiment of definition) above the stability of the PEG-rHuMGDF of A50S.
Embodiment 2
The pH evaluationA. parent material: PEG-rHuMGDFB. fills a prescription: the 10mM acetate, pH5.0,5% Sorbitol Powder (A50S) 10mM acetate, pH4.0,5% Sorbitol Powder (A40S) 10mM succinate, pH3.5,5% Sorbitol Powder (S35S) 10mM succinate, pH4.0,5% Sorbitol Powder (S40S) 10mM succinate, pH5.0,5% Sorbitol Powder (S50S) 10mM Histidine, pH6.0,5% Sorbitol Powder (H60S) 10mM imidazoles, pH6.0,5% Sorbitol Powder (160S) 10mM tartrate, pH4.0,5% Sorbitol Powder (T40S) 10mM glutaminate, pH4.0,5% Sorbitol Powder (E40S) 10mM phosphoric acid salt, pH6.0,5% Sorbitol Powder (P60S) 10mM phosphoric acid salt, pH7.0,5% Sorbitol Powder (P70S) 10mM Tris, pH8.0,5% Sorbitol Powder (T80S) 10mM Histidine, pH5.0,5% Sorbitol Powder (H50S) 10mM Histidine, pH6.0,5% Sorbitol Powder (H60S) 10mM Histidine, pH7.0,5% Sorbitol Powder (H70S) 10mM Histidine, pH8.0,5% Sorbitol Powder (H80S) C. phial: with the 0.5mg/ml protein concn 3cc phial 1mL that packs into.D. temperature and time point: 37 ℃; Time point provides in table.E. analyze: HPLC: size exclusion chromatography (SEC), reverse-phase chromatography (RP), ion-exchange chromatography (IEX).F. data
Table 6-11 is given in 37 ℃ and hatches after the fixed time by size exclusion, anti-phase and main peak percentage ratio that cation-exchange chromatography is measured.
PH evaluation-pass through after hatching the fixed time at 37 ℃
The main peak percentage ratio that size exclusion chromatography is measured
Table 6
Form. * Incubation time
T＝0 T=2 week T=4 week T=8 week T=12 week T=17 week
A40S 94.39 94.90 94.63 94.27 94.99 94.93 89.71 94.90 90.86 93.65 92.59 87.53 94.31 94.56 43.46 94.29 88.20 90.29 90.20 85.29 93.77 94.20 34.44 93.65 82.91 80.95 86.16 80.77 91.74 92.77 24.48 91.30 77.21 74.28 80.51 76.45 89.13 91.49 18.10 86.84 70.19 62.43 72.34 71.12 85.96 94.83 - 77.94
S35S
S40S
S50S
H60S
160S
T40S
E40S
*The Form.=prescription.
Table 7
Fom. * Incubation time
T＝0 T=3 days T=7 days T=10 days T=2 week T=3 week T=6 week T=12 week
T80S 97.70 97.53 97.62 97.62 97.70 97.65 97.81 97.72 93.56 94.20 97.02 96.64 - 95.55 96.45 96.28 91.28 94.22 97.24 96.75 94.68 96.84 95.84 95.43 88.12 94.37 97.09 95.86 93.27 96.35 94.83 95.45 86.63 94.54 94.50 95.37 92.03 96.38 94.12 95.63 80.25 92.94 96.19 94.33 89.36 95.77 91.77 94.71 66.18 91.76 95.12 90.95 81.52 93.76 84.81 93.97 46.58 89.18 91.68 84.34 69.65 89.16 71.14 91.65
H50S
H60S
H70S
H80S
P60S
P70S
A50S
PH evaluation-pass through after hatching the fixed time at 37 ℃
The main peak percentage ratio that reverse-phase chromatography is measured
Table 8
Prescription Incubation time
T＝0 T=2 week T=4 week T=8 week T=12 week T=17 week
A40S 93.49 93.78 93.91 93.49 93.65 93.68 93.65 93.67 91.69 90.10 91.61 92.59 90.54 92.61 88.04 92.39 84.34 80.86 83.89 88.93 86.69 87.64 74.51 86.03 78.87 70.36 77.16 85.96 86.49 87.34 66.08 80.64 70.55 59.35 - 79.35 80.88 84.11 53.87 71.50 64.23 50.98 59.22 73.71 76.11 79.49 - 65.23
S35S
S40S
S50S
H60S
160S
T40S
E40S
Table 9
Prescription Incubation time
Time 0 T=3 days T=7 days T=10 days T=2 week T=6 week T=12 week
T80S 95.96 96.14 95.88 95.78 95.88 96.49 96.04 96.02 93.75 95.38 94.32 92.66 94.11 94.62 94.98 95.13 92.68 95.52 94.77 93.84 93.23 94.82 94.14 95.57 88.57 94.70 94.65 90.72 90.94 94.18 92.41 94.68 87.98 97.08 94.08 90.95 89.66 93.44 94.37 96.35 68.58 92.18 90.20 - 77.82 86.25 82.67 92.78 48.84 88.45 84.80 70.83 67.64 81.09 71.11 89.30
H50S
H60S
H70S
H80S
P60S
P70S
A50S
PH evaluation-pass through after hatching the fixed time at 37 ℃
The main peak percentage ratio that cation-exchange chromatography is measured
Table 10
Prescription Incubation time
T＝0 T=2 week T=4 week T=8 week T=12 week T=17 week
A40S 81.17 82.64 82.16 82.86 82.32 83.72 79.23 82.37 73.84 72.97 74.54 75.30 79.60 80.20 30.25 75.53 69.66 67.10 70.95 67.91 75.57 77.95 27.58 69.71 53.96 52.36 53.81 58.14 70.77 72.15 19.37 59.80 43.09 45.84 44.63 49.48 65.47 64.05 11.92 50.91 41.14 37.70 34.96 41.49 - 66.01 - 47.72
S35S
S40S
S50S
H60S
160S
T40S
E40S
Table 11
Prescription Incubation time
Time 0 T=3 days T=7 days T=10 days T=2 week T=3 week T=6 week T=12 week
T80S 87.44 84.42 87.86 82.99 84.08 85.68 87.60 83.00 80.38 83.70 86.81 83.33 84.72 84.58 78.70 84.54 78.04 83.86 85.40 81.35 81.49 83.73 82.50 81.65 76.41 83.23 84.56 81.01 82.17 83.22 84.04 83.81 72.76 82.16 82.00 79.55 77.28 79.15 78.99 81.54 71.28 78.52 78.90 72.70 64.21 75.87 77.85 77.68 54.49 76.07 80.64 67.95 68.21 73.38 78.90 79.50 - 70.85 73.71 56.91 54.79 60.93 69.18 72.22
H50S
H60S
H70S
H80S
P60S
P70S
A50S
Embodiment 3
The evaluation of mpl ligand concentrationA. parent material: PEG-rHuMGDFB. fills a prescription: the 10mM acetate, pH5.0,5% Sorbitol Powder, 2.0mg/ml (20A5S) 10mM acetate, pH5.0,5% Sorbitol Powder, 1.0mg/ml (10A5S) 10mM acetate, pH5.0,5% Sorbitol Powder, 0.5mg/ml (05A5S) 10mM acetate, pH5.0,5% Sorbitol Powder, 0.2mg/ml (02A5S) C. phial: with the specified protein concn 3cc phial 1mL that packs into.D. temperature and time point: 37 ℃; Time point provides in table.E. analyze: HPLC:SEC, RP, IEX.F. data
Table 12-14 is given in 37 ℃ and hatches after the fixed time by size exclusion, anti-phase and main peak percentage ratio that cation-exchange chromatography is measured.
Mpl ligand concentration evaluation-at 37 ℃ of main peak percentage ratios after hatching the fixed time
Table 12
The size exclusion chromatogram
Prescription Incubation time
T＝0 T=1 week T=2 week T=3 week T=4 week T=8 week T=12 week
02A5S 05A5S 10A5S 20A5S 94.44 94.11 93.96 93.81 94.86 93.78 92.60 91.50 93.84 92.86 91.69 90.25 94.53 93.25 91.74 90.20 94.51 93.40 91.32 89.55 93.90 91.55 89.20 86.89 92.74 90.11 86.89 83.59
Table 13
Reverse-phase chromatography
Prescription Incubation time
T＝0 T=1 week T=2 week T=3 week T=4 week T=8 week T=12 week
02A5S 05A5S 10A5S 20A5S 94.53 94.73 94.86 94.67 93.41 94.44 94.56 94.12 93.28 93.30 93.25 93.07 92.16 92.41 92.39 92.47 91.05 91.97 91.98 91.79 88.89 89.18 88.06 88.37 87.90 85.97 87.62 87.07
Table 14
Cation-exchange chromatography
Prescription Incubation time
T＝0 T=1 week T=2 week T=4 week T=8 week T=12 week
02A5S 05A5S 10A5S 20A5S 79.40 78.22 - 79.52 65.75 67.44 66.18 76.71 78.56 80.26 80.80 82.09 79.80 81.10 82.02 81.38 74.42 76.27 75.81 74.26 59.74 61.39 60.72 60.89
Embodiment 4
The vehicle evaluationA. parent material: PEG-rHuMGDFB. fills a prescription: 10mM acetate, pH5.0,5% Sorbitol Powder
5mM EDTA (A5SE) 10mM acetate, pH5.0,2% L-Ala (A5A) 10mM acetate, pH5.0,1.6% glycine (A5G) 10mM acetate, pH5.0,2.7% proline(Pro) (A5P) 10mM acetate, pH5.0,3.5% Methionin (A5K) 10mM acetate, pH5.0,4.3% arginine (A5R) 10mM glutaminate, pH5.0,9.3% sucrose (E5Su) 10mM glutaminate, pH5.0,5% Sorbitol Powder (E5S) C. phial: with the 0.5mg/ml protein concn 3cc phial 1mL that packs into.D. temperature and time point: 37 ℃; Time point provides in table.E. analyze: HPLC:SEC, RP, IEX.F. data
Table 15-17 is given in 37 ℃ and hatches after the fixed time by size exclusion, anti-phase and main peak percentage ratio that cation-exchange chromatography is measured.
Vehicle evaluation-at 37 ℃ of main peak percentage ratios after hatching the fixed time
Table 15
The size exclusion chromatogram
Prescription Incubation time
T＝0 T=2 week T=4 week T=8 week T=12 week
A5R 84.71 94.30 94.57 86.75 93.08 94.66 94.78 94.55 21.83 91.40 91.22 17.24 60.01 91.97 93.07 91.57 19.01 91.95 91.43 15.02 54.53 92.16 93.55 92.18 12.30 88.36 92.26 9.76 43.22 87.63 90.68 88.13 - 86.52 84.50 - 37.75 85.05 92.28 85.89
E5Su
A5G
A5K
A5SE
A5P
E5S
A5A
Table 16
Cation-exchange chromatography
Prescription Incubation time
T＝0 T=2 week T=4 week T=8 week T=12 week
A5R 82.26 84.93 86.17 80.88 84.56 86.73 87.49 86.28 28.41 86.22 81.90 20.18 62.75 87.58 90.23 81.31 21.32 88.62 66.81 14.23 56.40 86.22 88.83 86.10 11.71 72.16 18.95 8.75 36.31 69.34 75.55 70.29 - 65.04 26.45 - 30.38 65.76 70.01 63.69
E5Su
A5G
A5K
A5SE
A5P
E5S
A5A
Table 17
Reverse-phase chromatography
Prescription Incubation time
T＝0 T=2 week T=4 week T=12 week
A5R 95.96 96.10 95.71 95.81 95.98 95.67 95.64 95.78 92.35 94.57 69.61 88.93 93.60 92.98 93.98 90.38 85.68 91.59 39.86 81.30 90.01 89.96 90.61 86.52 - 77.92 - - - 78.85 83.90 70.00
E5Su
A5G
A5K
A5SE
A5P
E5S
A5A
Embodiment 5
The isotonicity evaluationA. parent material: PEG-rHuMGDFB. fills a prescription: 10mM acetate, pH5.0,9.3% sucrose (A5SU) 10mM acetate, pH5.0,5% mannitol (A5MA) 10mM acetate, pH5.0,140mM sodium-chlor (A5N) 10mM acetate, pH5.0,2%PEG8000 (A5P8) 10mM acetate, pH5.0,2.5% glycerine (A5G) 10mM acetate, pH5.0,5% Sorbitol Powder
0.01%Tween 20 (A5ST) 10mM Histidine, pH6.0,5% Sorbitol Powder (H6S) 10mM Histidine, pH6.0,5% Sorbitol Powder,
0.001% xitix (H6AA) C. phial: with the 0.5mg/ml protein concn 3cc phial 1mL that packs into.D. temperature and time point: 37 ℃; Time point provides in table.E. analyze: HPLC:SEC, RP, IEX.F. data
Table 18-20 is given in 37 ℃ and hatches after the fixed time by size exclusion, anti-phase and main peak percentage ratio that cation-exchange chromatography is measured.
Isotonicity evaluation-at 37 ℃ of main peak percentage ratios after hatching the fixed time
Table 18
The size exclusion chromatogram
Prescription Incubation time
T＝0 T=3.5 days T=1 week T=2 week T=3 week T=7 week T=12 week
H6S 96.70 96.75 83.54 96.55 96.36 96.46 94.88 96.25 96.23 95.66 30.42 95.14 95.18 95.29 92.89 94.83 96.30 96.03 28.04 95.22 95.37 95.49 92.89 94.50 95.95 95.72 24.64 95.02 95.16 95.20 92.61 94.58 95.77 95.29 20.19 95.13 95.60 95.59 91.62 94.37 93.37 93.32 17.62 93.08 93.49 93.23 92.78 91.16 91.03 90.61 - 91.42 91.89 91.68 82.05 87.68
H6Aa
A5N
A5Ma
A5Su
A5G
A5P8
A5ST
Table 19
Reverse-phase chromatography
Prescription Incubation time
T＝0 T=3.5 days T=1 week T=2 week T=7 week T=12 week
H6S 95.49 95.64 94.94 95.90 95.55 95.57 94.75 94.57 94.39 92.00 93.99 95.05 95.39 94.78 91.31 93.24 94.69 90.67 92.19 95.29 94.78 95.51 87.07 93.90 85.55 93.02 89.52 94.34 93.47 94.88 76.93 82.75 87.60 74.22 68.67 90.13 88.19 90.04 13.41 87.61 85.62 66.22 - 87.22 82.88 88.64 - 85.45
H6Aa
A5N
A5Ma
A5Su
A5G
A5P8
A5ST
Table 20
Cation-exchange chromatography
Prescription Incubation time
T＝0 T=3.5 days T=1 week T=2 week T=3 week T=7 week T=12 week
H6S 87.13 85.12 79.98 84.73 82.98 82.79 85.65 85.02 85.79 80.75 39.01 84.37 84.83 84.69 82.26 83.83 84.67 79.31 29.14 84.43 83.46 85.09 81.74 83.95 82.66 75.99 25.03 81.92 80.76 81.73 77.41 80.02 82.77 75.23 20.77 83.07 81.09 81.61 74.77 79.79 79.32 64.62 14.67 78.17 76.61 76.98 53.74 74.56 59.35 45.93 - 58.52 56.85 59.03 4.80 55.85
H6Aa
A5N
A5Ma
A5Su
A5G
A5P8
A5ST
Embodiment 6
Antioxidant/sequestrant evaluationA. parent material: PEG-rHuMGDFB. fills a prescription: the 10mM acetate, pH5.0,5% Sorbitol Powder 3mM gsh (A5S GT) 10mM acetate, pH5.0,5% Sorbitol Powder 5mM methionine(Met) (A5S M) 10mM acetate, pH5.0,5% Sorbitol Powder 5mM methionine(Met) 1mM EDTA (A5S ME) 10mM acetate, pH5.0,5% Sorbitol Powder 1mM Citrate trianion (A5S C) 10mM acetate, pH5.0,5% Sorbitol Powder 0.5mM Citrate trianion (A5S 05C) 10mM acetate, pH5.0,5% Sorbitol Powder 1mM EDTA (A5S 1E) 10mM acetate, pH5.0,5% Sorbitol Powder 0.5mM EDTA (A5S E) C. phial: with the 0.5mg/ml protein concn 3cc phial 1mL that packs into.D. temperature and time point: 37 ℃; Time point provides in table.E. analyze: HPLC:SEC, RP, IEX.F. data
Table 21-23 passes through size exclusion after being given in 37 ℃ of insulation fixed times, the anti-phase main peak percentage ratio of measuring with cation-exchange chromatography.
The main peak percentage ratio of antioxidant/sequestrant evaluation-after 37 ℃ of insulation fixed times
Table 21
The size exclusion chromatogram
Prescription Incubation time
T＝0 T=2 week T=4 week T=9 week
A5SGT 16.69 94.53 94.88 94.30 93.96 94.88 94.80 12.32 91.03 92.15 90.83 90.95 90.75 91.72 8.03 89.72 90.73 88.14 88.98 89.15 89.89 5.91 89.00 85.74 79.61 - 80.63 82.06
A5SM
A5SME
A5SC
A5S05C
A5S1E
A5SE
Table 22
Reverse-phase chromatography
Prescription Incubation time
T＝0 T=2 week T=4 week T=9 week T=12 week
A5SGT 5.69 94.70 94.54 93.98 94.43 94.36 94.75 2.37 91.59 87.66 81.13 87.01 86.84 90.27 2.80 88.67 91.36 90.33 84.30 76.43 85.64 2.60 88.55 81.97 68.01 79.83 89.93 81.20 2.50 86.83 80.39 62.91 76.35 84.56 78.96
A5SM
A5SME
A5SC
A5S05C
A5S1E
A5SE
Table 23
Cation-exchange chromatography
Prescription Incubation time
T＝0 T=2 week T=4 week T=9 week
A5SGT 4.66 84.69 84.93 85.23 86.06 85.38 86.51 5.15 81.18 78.36 72.11 78.00 77.00 80.07 0.0 80.96 78.26 66.46 72.53 76.42 77.93 - 72.95 69.48 54.68 66.06 66.21 69.79
A5SM
A5SME
A5SC
A5S05C
A5S1E
A5SE
Embodiment 7
The stain remover evaluationA. parent material: PEG-rHuMGDFB. fills a prescription: all forms contain the 10mM acetate, pH5.0 and 5% Sorbitol Powder and 0.050mg/nl PEG-rHuMGDF.
004T20：0.004mg/ml Tween-20
006T20：0.006mg/ml Tween-20
010T20：0.010mg/ml Tween-20
040T20：0.040mg/ml Tween-20
060T20：0.060mg/ml Tween-20
004T80：0.004mg/ml Tween-80
006T80：0.006mg/ml Tween-80
010T80：0.010mg/ml Tween-80
040T80：0.040mg/ml Tween-80
060T80:0.060mg/ml Tween-80C. data
Table 24 provides the result based on the reversed-phase HPLC purity of main peak percentage ratio.
Table 24
Reverse-phase chromatography
Prescription Incubation time at 37 degrees centigrade
T＝0 T=2 week T=4 week T=6 week T=12 week
A5S 004T20 006T20 010T20 040T20 060T20 004T80 006T80 010T80 040T80 060T80 94.66 94.68 94.69 94.89 94.59 94.61 94.44 94.43 94.89 94.45 94.19 94.05 94.79 93.99 94.30 92.95 92.62 94.35 94.05 94.22 92.64 88.38 90.67 91.25 91.48 91.33 90.63 90.57 90.91 91.01 90.69 89.74 88.67 90.90 91.02 90.46 90.76 89.88 89.49 90.80 90.18 90.22 89.26 87.64 89.07 88.49 88.43 88.47 87.58 86.72 88.48 88.08 88.04 86.56 84.53
D. result:
Stain remover for example Tween can be included in the PEG-rHuMGDF prescription improving physical stability, and reclaims under the disadvantageous effect in that chemical stability is not had.Tween-20 and Tween-80 can join in the PEG-rHuMGDF prescription and not cause the oxidation of excessive methionine(Met) with the maximum approximately final concentrations of 0.060mg/ml.Tween-20 and Tween-80 are the most effective in the concentration range of 0.006mg/ml to 0.060mg/ml.
Embodiment 8
Freeze dried composition
Following table 25 has been summed up the data that obtain for the freeze dried composition that contains the mpl part.In each of these embodiment, the mpl part of test is PEG-rHuMGDF, and it comprises the amino acid/11-163 of SEQ ID NO:2, with the polyethylene group of the about 20kDa of molecular-weight average in the α of the-terminal amino acid one-PEG of amino place baseization.For table 25-27, before analysis, prepare freeze dried PEG-rHuMGDF once more, and the representative of main peak percentage ratio is as the rate of recovery of freeze-drying result's PEG-rHuMGDF with about 1ml water for injection.
Table 25
Prescription The main peak percentage ratio % that SEC measures
The 10mM Histidine, 5% mannitol 88
The 10mM Histidine, 4% mannitol, 1% sucrose 93
Annotate: the mpl ligand concentration is 0.5mg/ml.
For freeze dried sample, the pH6 that measures according to size exclusion, 7 and 8 o'clock, physical stability does not increase.
The sucrose concentration scope of research:
Table 26
Sucrose concentration The main peak percentage ratio % that SEC measures
2％ 91
4％ 94
5％ 97
6％ 95
The scope (10mM concentration) of the damping fluid of research:
Table 27
Prescription SEC, the main peak percentage ratio % that HPLC measures
Histidine, 3.8% mannitol, 2% sucrose, pH5 87
Citrate trianion, 3.8% mannitol, 2% sucrose, pH5 87
Acetate, 3.8% mannitol, 2% sucrose, pH5 79
Succinate, 3.8% mannitol, 2% sucrose, pH5 88
MES, 3.8% mannitol, 2% sucrose, pH5 88
Phosphoric acid salt, 3.8% mannitol, 2% sucrose, pH7 87
Phosphoric acid salt, 3.8% mannitol, 0.5% glycine, pH7 80
All stablizers for example amino acid (for example wait and ooze arginine, Methionin, proline(Pro) and Histidine) and amorphous reagent (for example trehalose and PEG) do not show the stability of raising during freeze-drying.
Prescription with the best main peak rate of recovery and minimum cohesion level:
The 10mM glutaminate, 6% sucrose, 2% mannitol, pH5.0
Though described the present invention with embodiment preferred, but be not limited to disclosed embodiment, on the contrary, meaning will cover modification and the Equivalent in the various accessory claim book spirit and scope, and the wideest explanation of its scope record can comprise modification and the Equivalent that all are such.
Sequence table (1) general information:
(i) applicant: AMGEN INC.
(ii) invention exercise question: the pharmaceutical composition that contains the mpl part
(iii) sequence number: 2
(iv) contact address:
(A) address: AMGEN INC.
(B) street: 1849 DeHavilland Drive
(C) city: Thousand Oaks
(D) state: California
(E) country: the U.S.
(F) by compiling (ZIP): 91320-1789
(V) computer-reader form:
(A) Floppy dish
(B) computer: IBM PC compatibility
(C) operating system: PC-DOS/MS-DOS
(D) floppy disk: Patent In Release#1.0, Version#1.30
(Vi) current request for data:
(A) application number: US (also not registration)
(B) applying date: 04-10-1996
(C) classification:
(Viii) proxy/business quarters's information:
(A) title: COOK Ph.D., Robert R.
(B) registration number: 31602
(C) information of reference/recording mechanism: A-412 (2) SEQ ID NO:1:
(i) sequence signature:
(A) length: 1342 base pairs
(B) type: nucleic acid
(C) chain number: the unknown
(D) topology: the unknown
(ii) molecule type: cDNA
(ix) feature:
(A) noun/keyword: CDS
(B) position: 36..1097
(ix) feature:
(A) noun/keyword: mat-peptide
(B) position: 99..1097
(ix) feature:
(A) noun/keyword: sig-peptide
(B) position: 36..98 (xi) sequence description: SEQ ID NO:1:CAGGGAGCCA CGCCAGCCAA GACACCCCGG CCAGA ATG GAG CTG ACT GAA TTG 53
Met Glu Leu Thr Glu Leu
-21 -20CTC CTC GTG GTC ATG CTT CTC CTA ACT GCA AGG CTA ACG CTG TCC AGC 101Leu Leu Val Val Met Leu Leu Leu Thr Ala Arg Leu Thr Leu Ser Ser-15 -10 -5 1CCG GCT CCT CCT GCT TGT GAC CTC CGA GTC CTC AGT AAA CTG CTT CGT 149Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg
5 10 15GAC TCC CAT GTC CTT CAC AGC AGA CTG AGC CAG TGC CCA GAG GTT CAC 197Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His
20 25 30CCT TTG CCT ACA CCT GTC CTG CTG CCT GCT GTG GAC TTT AGC TTG GGA 245Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly
35 40 45GAA TGG AAA ACC CAG ATG GAG GAG ACC AAG GCA CAG GAC ATT CTG GGA 293Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Leu Gly50 55 60 65GCA GTG ACC CTT CTG CTG GAG GGA GTG ATG GCA GCA CGG GGA CAA CTG 34lAla Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln Leu
70 75 80GGA CCC ACT TGC CTC TCA TCC CTC CTG GGG CAG CTT TCT GGA CAG GTC 389Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val
85 90 95CGT CTC CTC CTT GGG GCC CTG CAG AGC CTC CTT GGA ACC CAG CTT CCT 437Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro
100 105 110CCA CAG GGC AGG ACC ACA GCT CAC AAG GAT CCC AAT GCC ATC TTC CTG 485Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu
115 120 125AGC TTC CAA CAC CTG CTC CGA GGA AAG GTG CGT TTC CTG ATG CTT GTA 533Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val130 135 140 145GGA GGG TCC ACC CTC TGC GTC AGG CGG GCC CCA CCC ACC ACA GCT GTC 581Gly Gly Ser Thr Leu Cys Val Arg Arg Ala Pro Pro Thr Thr Ala Val
150 155 160CCC AGC AGA ACC TCT CTA GTC CTC ACA CTG AAC GAG CTC CCA AAC AGG 629Pro Ser Arg Thr Ser Leu Val Leu Thr Leu Asn Glu Leu Pro Asn Arg
165 170 175ACT TCT GGA TTG TTG GAG ACA AAC TTC ACT GCC TCA GCC AGA ACT ACT 677Thr Ser Gly Leu Leu Glu Thr Asn Phe Thr Ala Ser Ala Arg Thr Thr
180 185 190GGC TCT GGG CTT CTG AAG TGG CAG CAG GGA TTC AGA GCC AAG ATT CCT 725Gly Ser Gly Leu Leu Lys Trp Gln Gln Gly Phe Arg Ala Lys Ile Pro
195 200 205GGT CTG CTG AAC CAA ACC TCC AGG TCC CTG GAC CAA ATC CCC GGA TAC 773Gly Leu Leu Asn Gln Thr Ser Arg Ser Leu Asp Gln Ile Pro Gly Tyr210 215 220 225CTG AAC AGG ATA CAC GAA CTC TTG AAT GGA ACT CGT GGA CTC TTT CCT 821Leu Asn Arg Ile His Glu Leu Leu Asn Gly Thr Arg Gly Leu Phe Pro
230 235 240GGA CCC TCA CGC AGG ACC CTA GGA GCC CCG GAC ATT TCC TCA GGA ACA 869Gly Pro Ser Arg Arg Thr Leu Gly Ala Pro Asp Ile Ser Ser Gly Thr
245 250 255TCA GAC ACA GGC TCC CTG CCA CCC AAC CTC CAG CCT GGA TAT TCT CCT 917Ser Asp Thr Gly Ser Leu Pro Pro Asn Leu Gln Pro Gly Tyr Ser Pro
260 265 270TCC CCA ACC CAT CCT CCT ACT GGA CAG TAT ACG CTC TTC CCT CTT CCA 965Ser Pro Thr His Pro Pro Thr Gly Gln Tyr Thr Leu Phe Pro Leu Pro
275 280 285CCC ACC TTG CCC ACC CCT GTG GTC CAG CTC CAC CCC CTG CTT CCT GAC 1013Pro Thr Leu Pro Thr Pro Val Val Gln Leu His Pro Leu Leu Pro Asp290 295 300 305CCT TCT GCT CCA ACG CCC ACC CCT ACC AGC CCT CTT CTA AAC ACA TCC 1061Pro Ser Ala Pro Thr Pro Thr Pro Thr Ser Pro Lau Leu Asn Thr Ser
310 315 320TAC ACC CAC TCC CAG AAT CTG TCT CAG GAA GGG TAA GGTTCTCAGA 1107Tyr Thr His Ser Gln Asn Leu Ser Gln Glu Gly *
The information of 325 330CACTGCCGAC ATCAGCATTG TCTCGTGTAC AGCTCCCTTC CCTGCAGGGC GCCCCTGGGA 1167GACAACTGGA CAAGATTTCC TACTTTCTCC TGAAACCCAA AGCCCTGGTA AAAGGGATAC 1227ACAGGACTGA AAAGGGAATC ATTTTTCACT GTACATTATA AACCTTCAGA AGCTATTTTT 1287TTAAGCTATC AGCAATACTC ATCAGAGCAG CTAGCTCTTT GGTCTATTTT CTGCA, 1342 (2) SEQ ID NO:2:
(i) sequence signature:
(A) length: 354 amino acid
(B) type: amino acid
(D) topology: linearity
(ii) molecule type: protein
(xi) sequence description: SEQ ID NO:2:Met Glu Leu Thr Glu Leu Leu Leu Val Val Met Leu Leu Leu Thr Ala-21-20-15-10Arg Leu Thr Leu Ser Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val-5,15 10Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser
15 20 25Gln Cys Pro Glu Val His Pro Leu pro Thr Pro Val Leu Leu Pro Ala
30 35 40Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys
45 50 55Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Mec60 65 70 75Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly
80 85 90Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu
95 100 105Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp
110 115 120Pro Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val
125 130 135Arg Phe Leu Mec Leu Val Gly Gly Ser Thr Leu Cys Val Arg Arg Ala140 145 150 155Pro Pro Thr Thr Ala Val Pro Ser Arg Thr Ser Leu Val Leu Thr Leu
160 165 170Asn Glu Leu Pro Asn Arg Thr Ser Gly Leu Leu Glu Thr Asn Phe Thr
175 180 185Ala Ser Ala Arg Thr Thr Gly Ser Gly Leu Leu Lys Trp Gln Gln Gly
190 195 200Phe Arg Ala Lys Ile Pro Gly Leu Leu Asn Gln Thr Ser Arg Ser Leu
205 210 215Asp Gln Ile Pro Gly Tyr Leu Asn Arg Ile His Glu Leu Leu Asn Gly220 225 230 235Thr Arg Gly Leu Phe Pro Gly Pro Ser Arg Arg Thr Leu Gly Ala Pro
240 245 250Asp Ile Ser Ser Gly Thr Ser Asp Thr Gly Ser Leu Pro Pro Asn Leu
255 260 265Gln Pro Gly Tyr Ser Pro Ser Pro Thr His Pro Pro Thr Gly Gln Tyr
270 275 280Thr Leu phe Pro Leu Pro Pro Thr Leu Pro Thr Pro Val Val Gln Leu
285 290 295His Pro Leu Leu Pro Asp Pro Ser Ala Pro Thr Pro Thr Pro Thr Ser300 305 310 315Pro Leu Leu Asn Thr Ser Tyr Thr His Ser Gln Asn Leu Ser Gln Glu
320 325 330Gly *

Claims (21)

1. stable medicinal compositions, it contains the mpl ligand derivatives that polyoxyethylene glycol wherein links to each other with the mpl part; Be selected from glutaminate, phosphoric acid salt, Histidine, the buffer reagent of imidazoles and acetate; Be selected from Sorbitol Powder, sucrose, mannitol, glycerine, the vehicle of polyoxyethylene glycol and nonpolar amino acid; Do not contain lipid; Has pH scope 5-6.
2. the composition of claim 1, wherein the mpl part comprises the amino acid fragment 7-151 of SEQ ID NO:2 at least.
3. the composition of claim 1, wherein any is formed among the amino acid fragment 1-151 to 1-191 of mpl part by SEQ ID NO:2.
4. the composition of claim 1, wherein any is formed among the amino acid fragment 1-151 to 1-171 of mpl part by SEQ ID NO:2.
5. the composition of claim 1, wherein the mpl part is made up of the amino acid fragment 1-151 of SEQ ID NO:2.
6. the composition of claim 1, wherein the mpl part is made up of the amino acid fragment 1-163 of SEQ ID NO:2.
7. the composition of claim 6 wherein contains the acetate as buffer reagent, and as the Sorbitol Powder of vehicle, and in water medium, pH is 5.
8. the composition of claim 1, wherein nonpolar amino acid is selected from glycine, proline(Pro) and L-Ala.
9. the composition of claim 1, wherein any is formed among the amino acid fragment 1-151 to 1-191 of mpl part by SEQ ID NO:2, and described composition further contains antioxidant.
10. the composition of claim 9, wherein antioxidant is selected from EDTA, xitix, gsh, methionine(Met) and Citrate trianion.
11. the composition of claim 1 further contains stain remover.
12. the composition of claim 11, wherein stain remover is selected from Tween; Brij 35; Pluronics; Sodium lauryl sulphate; Triton; The PEG-40 Viscotrol C; Oleyl-3-phosphoric acid salt; Diethanolamine oleyl-10-phosphoric acid salt.
13. the composition of claim 1, wherein composition is in the water medium.
14. the composition of claim 1, wherein composition is the freeze-drying form.
15. the composition of claim 1, it contains phosphate buffer, 5% Sorbitol Powder, and in water medium, pH is 6.
16. the composition of claim 1 contains histidine buffer and 5% Sorbitol Powder in its water medium.
17. the composition of claim 1 contains imidazole buffer agent and 5% Sorbitol Powder in its water medium.
18. the composition of claim 1 contains glutaminate buffer reagent and 5% Sorbitol Powder in its water medium.
19. the composition of claim 1 contains the glutaminate buffer reagent in its water medium, 5% Sorbitol Powder, pH are 5.
20. the composition of claim 1 contains the glutaminate buffer reagent in its lyophilized form, 6% sucrose, and 2% mannitol, pH are 5.
21. the composition of claim 1, wherein the mpl part is made up of the amino acid/11-332 of SEQ ID NO:2.
CNB971802777A 1996-10-04 1997-09-12 Pharmaceutical compsns. containing an MPL ligand Expired - Fee Related CN1142940C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72612396A 1996-10-04 1996-10-04
US08/726,123 1996-10-04

Publications (2)

Publication Number Publication Date
CN1239480A CN1239480A (en) 1999-12-22
CN1142940C true CN1142940C (en) 2004-03-24

Family

ID=24917340

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB971802777A Expired - Fee Related CN1142940C (en) 1996-10-04 1997-09-12 Pharmaceutical compsns. containing an MPL ligand

Country Status (7)

Country Link
JP (1) JP2001501619A (en)
KR (1) KR100408229B1 (en)
CN (1) CN1142940C (en)
AU (1) AU4344697A (en)
HK (1) HK1024490A1 (en)
TW (1) TW561050B (en)
WO (1) WO1998014476A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8357513B1 (en) 1994-01-03 2013-01-22 Genentech, Inc. Nucleic acids encoding mpl ligand (thrombopoietin) and fragments thereof
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
PT1491208E (en) * 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Stabilized liquid pharmaceutical compositions containing tfpi
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
WO2002015926A1 (en) * 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha c-mpl LIGAND-CONTAINING MEDICINAL COMPOSITIONS FOR INCREASING PLATELETS AND ERYTHROCYTES
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
JP4664684B2 (en) * 2002-12-13 2011-04-06 ザイモジェネティクス， インコーポレイテッド Production of IL-21 in prokaryotic hosts
BRPI0412332A (en) 2003-07-07 2006-09-05 Hills Pet Nutrition Inc method for raising blood antioxidant levels in a feline, and, dietary composition suitable for feeding young pet animals
JO3324B1 (en) * 2006-04-21 2019-03-13 Amgen Inc Lyophilized Therapeutic Peptibody Formulations
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
ES2748526T3 (en) * 2006-12-21 2020-03-17 Amgen Inc Stable buffered formulations containing polypeptides
AU2014201388C1 (en) * 2006-12-21 2017-02-02 Amgen Inc. Stable Buffered Formulations Containing Polypeptides
CN102552184A (en) * 2012-02-16 2012-07-11 山东泉港药业有限公司 Thrombopoietin peptide analogue freeze-dried preparation
EP3916013A1 (en) 2012-09-20 2021-12-01 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
JP6595132B2 (en) * 2016-06-16 2019-10-23 ヤンセン ファッシンズ アンド プリベンション ベーフェー HIV vaccine preparation
EP3710063A1 (en) * 2017-11-16 2020-09-23 Amgen Inc. Stable compositions of pegylated carfilzomib compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
SK166695A3 (en) * 1994-03-31 1997-02-05 Amgen Inc Mgdf polypeptide for stimulating growth and megakaryocyte differentiation
MX9705943A (en) * 1995-02-15 1997-10-31 Amgen Inc Mpl ligand analogs.
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only

Also Published As

Publication number Publication date
KR100408229B1 (en) 2003-12-01
AU4344697A (en) 1998-04-24
KR20000048905A (en) 2000-07-25
JP2001501619A (en) 2001-02-06
HK1024490A1 (en) 2000-10-13
WO1998014476A1 (en) 1998-04-09
CN1239480A (en) 1999-12-22
TW561050B (en) 2003-11-11

Similar Documents

Publication Publication Date Title
CN1142940C (en) Pharmaceutical compsns. containing an MPL ligand
CN1071760C (en) N-terminally chemically modified protein compositions and methods
CN1241548C (en) Stable protein: phospholipid composition and method
CN1184233C (en) Erythrocyte-stimulating factor coupling
CN1103782C (en) Compositions and methods for stimulating megakaryocyte growth and differentiation
CN1245216C (en) Stabilized liquid polypeptide-confg. pharmaceutical compositions
CN1236370A (en) Chemically modified polypeptides
CN1333785A (en) Interferon-beta fusion proteins and uses
CN1165539A (en) Modification of peptide and protein
CN1159830A (en) Immunomodulators
CN1227604A (en) Multivarient IL-3 hematopoiesis fusion protein
CN1220670A (en) Inhibitor and stimulator of stem cell proliferationa and use thereof
CN1173183A (en) Conjugates of BDNF and NT-3 with a water-soluble polymer
CN1150458A (en) Hybrid molecule of formula GM-CSF-L-EPO or EPO-L-GM-CSF for hematopoietic stimulation
CN101080420A (en) A thymus-specific protein
CN1861634A (en) Dog interferon alpha, preparation process and use thereof
CN1284134A (en) Methods of producing anti-angiogenic proteins: endostation, angiostation or restin, using pichia yeast expression system
EP0426521A1 (en) Use of interleukine 2 for the treatment of leukemias
CN1533808A (en) Composition for treating coronavirus infection and SARS and method
CN1143325A (en) Method for selective methionine starvation of malignant cells in mammals
CN1433324A (en) Interferon gamma conjugates
CN1227027C (en) Novel compositions
CN1684978A (en) Glycosylated human granulocyte colony-stimulating factor (G-CSF) isoform
CN87108308A (en) New polypeptide and production thereof
TW420688B (en) Mpl ligand analogs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1024490

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040324

Termination date: 20100912